Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery

Koh Arakawa, Kousukue Hagisawa, Hiroyuki Kusano, Satoru Yoneyama, Akira Kurita, Tsunenori Arai, Makoto Kikuchi, Isao Sakata, Shin Ichirou Umenura, Fumitaka Ohsuzu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background - In-stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. Methods and Results - Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm2) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31±0.07 versus 1.38±0.47, 1.66±0.71, and 1.61±0.42 mm2, respectively; P <0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71±0.22 versus 2.53±1.39, 2.48±0.60, and 3.45±1.42 mm2; P <0.05). Conclusions - Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.

Original languageEnglish
Pages (from-to)149-151
Number of pages3
JournalCirculation
Volume105
Issue number2
DOIs
Publication statusPublished - 2002 Jan 15
Externally publishedYes

Fingerprint

Iliac Artery
Hyperplasia
Stents
Rabbits
Group Psychotherapy
Tunica Intima
Therapeutics
Control Groups
Intravenous Administration
13,17-bis(1-carboxypropionyl)carbamoylethyl-3-ethenyl-8-ethoxyiminoethylidene-7-hydroxy-2,7,12,18-tetramethyl porphyrin
Arteries
Body Weight
Water
Growth
Neoplasms

Keywords

  • Restenosis
  • Sonodynamic therapy
  • Stents
  • Ultrasonics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Arakawa, K., Hagisawa, K., Kusano, H., Yoneyama, S., Kurita, A., Arai, T., ... Ohsuzu, F. (2002). Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery. Circulation, 105(2), 149-151. https://doi.org/10.1161/hc0202.102921

Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery. / Arakawa, Koh; Hagisawa, Kousukue; Kusano, Hiroyuki; Yoneyama, Satoru; Kurita, Akira; Arai, Tsunenori; Kikuchi, Makoto; Sakata, Isao; Umenura, Shin Ichirou; Ohsuzu, Fumitaka.

In: Circulation, Vol. 105, No. 2, 15.01.2002, p. 149-151.

Research output: Contribution to journalArticle

Arakawa, K, Hagisawa, K, Kusano, H, Yoneyama, S, Kurita, A, Arai, T, Kikuchi, M, Sakata, I, Umenura, SI & Ohsuzu, F 2002, 'Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery', Circulation, vol. 105, no. 2, pp. 149-151. https://doi.org/10.1161/hc0202.102921
Arakawa K, Hagisawa K, Kusano H, Yoneyama S, Kurita A, Arai T et al. Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery. Circulation. 2002 Jan 15;105(2):149-151. https://doi.org/10.1161/hc0202.102921
Arakawa, Koh ; Hagisawa, Kousukue ; Kusano, Hiroyuki ; Yoneyama, Satoru ; Kurita, Akira ; Arai, Tsunenori ; Kikuchi, Makoto ; Sakata, Isao ; Umenura, Shin Ichirou ; Ohsuzu, Fumitaka. / Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery. In: Circulation. 2002 ; Vol. 105, No. 2. pp. 149-151.
@article{8325f67bcfd547f09b622e7bb51f16f5,
title = "Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery",
abstract = "Background - In-stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. Methods and Results - Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm2) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31±0.07 versus 1.38±0.47, 1.66±0.71, and 1.61±0.42 mm2, respectively; P <0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71±0.22 versus 2.53±1.39, 2.48±0.60, and 3.45±1.42 mm2; P <0.05). Conclusions - Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.",
keywords = "Restenosis, Sonodynamic therapy, Stents, Ultrasonics",
author = "Koh Arakawa and Kousukue Hagisawa and Hiroyuki Kusano and Satoru Yoneyama and Akira Kurita and Tsunenori Arai and Makoto Kikuchi and Isao Sakata and Umenura, {Shin Ichirou} and Fumitaka Ohsuzu",
year = "2002",
month = "1",
day = "15",
doi = "10.1161/hc0202.102921",
language = "English",
volume = "105",
pages = "149--151",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery

AU - Arakawa, Koh

AU - Hagisawa, Kousukue

AU - Kusano, Hiroyuki

AU - Yoneyama, Satoru

AU - Kurita, Akira

AU - Arai, Tsunenori

AU - Kikuchi, Makoto

AU - Sakata, Isao

AU - Umenura, Shin Ichirou

AU - Ohsuzu, Fumitaka

PY - 2002/1/15

Y1 - 2002/1/15

N2 - Background - In-stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. Methods and Results - Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm2) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31±0.07 versus 1.38±0.47, 1.66±0.71, and 1.61±0.42 mm2, respectively; P <0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71±0.22 versus 2.53±1.39, 2.48±0.60, and 3.45±1.42 mm2; P <0.05). Conclusions - Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.

AB - Background - In-stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. Methods and Results - Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm2) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31±0.07 versus 1.38±0.47, 1.66±0.71, and 1.61±0.42 mm2, respectively; P <0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71±0.22 versus 2.53±1.39, 2.48±0.60, and 3.45±1.42 mm2; P <0.05). Conclusions - Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.

KW - Restenosis

KW - Sonodynamic therapy

KW - Stents

KW - Ultrasonics

UR - http://www.scopus.com/inward/record.url?scp=0037080530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037080530&partnerID=8YFLogxK

U2 - 10.1161/hc0202.102921

DO - 10.1161/hc0202.102921

M3 - Article

C2 - 11790692

AN - SCOPUS:0037080530

VL - 105

SP - 149

EP - 151

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -